10/550,039B 8-4-06
FD 3/16/2004
PRD 3/20/2003

Connecting via Winsock to STN

Welcome to STN International! Enter x:

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptaylc1626

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS 4	APR 04	STN AnaVist $500 visualization usage credit offered
NEWS 5	MAY 10	CA/CAplus enhanced with 1900-1906 U.S. patent records
NEWS 6	MAY 11	KOREAPAT updates resume
NEWS 7	MAY 19	Derwent World Patents Index to be reloaded and enhanced
NEWS 8	MAY 30	IPC 8 Rolled-up Core codes added to CA/CAplus and USPATFULL/USPAT2
NEWS 9	MAY 30	The F-Term thesaurus is now available in CA/CAplus
NEWS 10	JUN 02	The first reclassification of IPC codes now complete in INPADOC
NEWS 11	JUN 26	TULSA/TULSA2 reloaded and enhanced with new search and and display fields
NEWS 12	JUN 28	Price changes in full-text patent databases EPFULL and PCTFULL
NEWS 13	JUl 11	CHEMSAFE reloaded and enhanced
NEWS 14	JUl 14	FSTA enhanced with Japanese patents
NEWS 15	JUl 19	Coverage of Research Disclosure reinstated in DWPI

NEWS EXPRESS JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8
NEWS X25	X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:09:33 ON 04 AUG 2006

=> g
G IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 14:09:50 ON 04 AUG 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 2 AUG 2006 HIGHEST RN 898176-03-9
DICTIONARY FILE UPDATES: 2 AUG 2006 HIGHEST RN 898176-03-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Documents and Settings\ychu\Desktop\Case\10550039\10550039a.str

L1 STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 14:10:10 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 9 TO ITERATE

100.0% PROCESSED 9 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 9 TO 360
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=>
Uploading C:\Documents and Settings\ychu\Desktop\Case\10550039\10550039.str

L3 STRUCTURE UPLOADED

=>
Uploading C:\Documents and Settings\ychu\Desktop\Case\10550039\10550039b.str

L4 STRUCTURE UPLOADED

=> d
L4 HAS NO ANSWERS
L4 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l4
SAMPLE SEARCH INITIATED 14:12:33 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 67 TO ITERATE

100.0% PROCESSED 67 ITERATIONS 1 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 849 TO 1831
PROJECTED ANSWERS: 1 TO 80

```
L5             1 SEA SSS SAM L4

=> s l4 full
FULL SEARCH INITIATED 14:12:54 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     1439 TO ITERATE

100.0% PROCESSED     1439 ITERATIONS                                 55 ANSWERS
SEARCH TIME: 00.00.01

L6            55 SEA SSS FUL L4

=> file caplus
COST IN U.S. DOLLARS                                  SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                     168.70     168.91

FILE 'CAPLUS' ENTERED AT 14:13:00 ON 04 AUG 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 4 Aug 2006  VOL 145 ISS 7
FILE LAST UPDATED: 3 Aug 2006  (20060803/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l6
L7             9 L6

=> d ibib abs hitstr tot

L7   ANSWER 1 OF 9  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         2005:409511  CAPLUS
DOCUMENT NUMBER:          142:463731
TITLE:                    A preparation of novel oxazolidinone derivatives,
                          useful as antibacterial agents
INVENTOR(S):              Kang, Jae-Hoon; Park, Chun-Ho; Kwon, Jin-Sun
PATENT ASSIGNEE(S):       Il-Dong Pharm. Co., Ltd., S. Korea
SOURCE:                   PCT Int. Appl., 28 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
     WO 2005042523         A1    20050512    WO 2004-KR2805          20041103
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
```

GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK,
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO,
NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO,
SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG

PRIORITY APPLN. INFO.: KR 2003-77372 A 20031103
KR 2004-82328 A 20041014
OTHER SOURCE(S): CASREACT 142:463731; MARPAT 142:463731

GI



I



II



III

AB The invention relates to a prepn. of novel oxazolidinone derivs. of formula I (R is H, amide, aldehyde, or nitrile, etc.; each X is independently N or CH), useful as antibacterial agents. For instance, oxazolidinone deriv. II [MIC (.mu.g/mL): str. pyogenes 77A - 0.4, s. aureus 285 - 0.8, MRSA 2 - 1.6; LD50 >5000 mg/kg] was prepd. via 1,3-dipolar cycloaddn. of vinyl acetate to (azidomethyl)oxazolidinone deriv. III with a yield of 74%.

IT 851529-97-0P 851529-98-1P
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of novel oxazolidinone derivs. useful as antibacterial agents)

RN 851529-97-0 CAPLUS

CN 1H-1,2,3-Triazole-4-carboxaldehyde, 1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 851529-98-1 CAPLUS
CN 1H-1,2,3-Triazole-4-carboxaldehyde, 1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, 4-oxime (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



IT 851530-02-4P
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of novel oxazolidinone derivs. useful as antibacterial agents)
RN 851530-02-4 CAPLUS
CN 1H-Pyrazole-4-carbonitrile, 1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 851529-96-9P 851530-00-2P 851530-01-3P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(prepn. of novel oxazolidinone derivs. useful as antibacterial agents)

RN 851529-96-9 CAPLUS

CN 2-Oxazolidinone, 3-[4-[4-(diethoxymethyl)-1H-1,2,3-triazol-1-yl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 851530-00-2 CAPLUS

CN 1H-Pyrazole-4-carboxylic acid, 1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 851530-01-3 CAPLUS

CN 1H-Pyrazole-4-carboxamide, 1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 851529-85-6P 851529-86-7P 851529-99-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of novel oxazolidinone derivs. useful as antibacterial agents)

RN 851529-85-6 CAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(1H-1,2,3-triazol-1-yl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 851529-86-7 CAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(2H-tetrazol-2-yl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 851529-99-2 CAPLUS
CN 1H-1,2,3-Triazole-4-carbonitrile, 1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:799584 CAPLUS
DOCUMENT NUMBER: 141:296028
TITLE: Preparation of azolylmethyloxazolidinones as antibacterials.
INVENTOR(S): Gravestock, Michael Barry; Hales, Neil James; Hauck, Sheila Irene
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 72 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004083206	A1	20040930	WO 2004-GB1132	20040316
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1603903	A1	20051214	EP 2004-720909	20040316
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
US 2006079695	A1	20060413	US 2005-550038	20050921
PRIORITY APPLN. INFO.:			GB 2003-6357 A	20030320
			WO 2004-GB1132 W	20040316

OTHER SOURCE(S): MARPAT 141:296028
GI



AB Title compds. [I; HET = pyrazolyl, imidazolyl, triazolyl, tetrazolyl; Q = (substituted) azolylphenyl, azolylpyridinyl, azolyloxazolyl, azolylthiazolyl, etc.], were prepd. Thus, (R)-3-(3-fluoro-4-iodophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one (prepn. given), (PPh3)2PdCl2, and 5-tributylstannyl-3-methylisoxazole were heated together at 100.degree. in dioxane for 16 h to give title compd. (II). II showed a min. inhibitory concn. of 1 .mu.g/mL against Staphylococcus aureus MSQS (methicillin resistant and quinolone resistant).

IT 765286-96-2P 765286-97-3P 765286-98-4P
765286-99-5P 765287-00-1P 765287-01-2P

765287-02-3P 765287-03-4P 765287-04-5P
765287-05-6P 765287-06-7P 765287-18-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of azolylmethyloxazolidinones as antibacterials)

RN 765286-96-2 CAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(3-methyl-5-isoxazolyl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 765286-97-3 CAPLUS
CN 3-Isoxazolecarboxylic acid, 5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 765286-98-4 CAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[3-(hydroxymethyl)-5-isoxazolyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 765286-99-5 CAPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[3-[(phosphonooxy)methyl]-5-isoxazolyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 765287-00-1 CAPLUS
CN 1H-Pyrazole-5-carbonitrile, 1-methyl-3-[4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 765287-01-2 CAPLUS
CN 1H-Pyrazole-5-carboxaldehyde, 1-methyl-3-[4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 765287-02-3 CAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(1H-1,2,3-triazol-4-yl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 765287-03-4 CAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(1-methyl-1H-1,2,3-triazol-4-yl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 765287-04-5 CAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(2-methyl-2H-1,2,3-triazol-4-yl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 765287-05-6 CAPLUS
CN 1H-1,2,3-Triazole-1-acetonitrile, 4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 765287-06-7 CAPLUS
CN 2H-1,2,3-Triazole-2-acetonitrile, 4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 765287-18-1 CAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[3-[(phosphonooxy)methyl]-5-isoxazolyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, disodium salt, (5R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



● 2 Na

IT 765287-07-8P 765287-15-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of azolylmethyloxazolidinones as antibacterials)

RN 765287-07-8 CAPLUS
CN Phosphoric acid, bis(1,1-dimethylethyl) [5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-3-isoxazolyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 765287-15-8 CAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[1-[(4-methoxyphenyl)methyl]-1H-1,2,3-triazol-4-yl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



Current application

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:799583 CAPLUS
DOCUMENT NUMBER: 141:314336
TITLE: Preparation of 1,3-oxazolidin-2-one derivatives as antibacterial agents
INVENTOR(S): Gravestock, Michael Barry; Hales, Neil James; Hauck, Sheila Irene
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 70 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004083205	A1	20040930	WO 2004-GB1119	20040316

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,

ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
TD, TG
EP 1603904 A1 20051214 EP 2004-720912 20040316
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK
US 2006084810 A1 20060420 US 2005-550039 20050921
PRIORITY APPLN. INFO.: GB 2003-6358 A 20030320
WO 2004-GB1119 W 20040316
OTHER SOURCE(S): MARPAT 141:314336
GI



I



II

AB Title compds. represented by the formula I [wherein N-HET = (un)substituted 1-pyrazolyl, 1-imidazolyl, 1,2,3-triazol-1-yl, etc.; Q = (un)substituted heteroaryl Ph, pyridinyl, thienyl, etc.; and pharmaceutically acceptable salts or an in-vivo hydrolyzable ester thereof] were prepd. as MAO-A (mono-amine oxidase) inhibitors. For example, coupling reaction of (5R)-3-(3-Fluoro-4-iodophenyl)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one with 5-(tributylstannyl)-3-methylisoxazole gave II. II showed decreased MAO-A potency with Ki value of 21 .mu.g/mL. Thus, I and their pharmaceutical compns. are useful as antibacterial agents.

IT 765912-32-1P 765912-34-3P 765912-36-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 1,3-oxazolidin-2-one derivs. as MAO-A inhibitors)

RN 765912-32-1 CAPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-(3-methyl-5-isoxazolyl)phenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 765912-34-3 CAPLUS
CN 2-Oxazolidinone, 3-[4-(3-isoxazolyl)phenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 765912-36-5 CAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[1-(phenylmethyl)-1H-1,2,3-triazol-4-yl]phenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:550955 CAPLUS
DOCUMENT NUMBER: 141:89124
TITLE: A preparation of oxazolidinone derivatives, useful as antibacterial agents
INVENTOR(S): Gravestock, Michael Barry; Hales, Neil James; Huynh, Hoan Khai
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 117 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004056817	A1	20040708	WO 2003-GB5448	20031215
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003292422	A1	20040714	AU 2003-292422	20031215
EP 1572688	A1	20050914	EP 2003-768000	20031215
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006512352	T2	20060413	JP 2004-561616	20031215
US 2006058314	A1	20060316	US 2005-539482	20050617

PRIORITY APPLN. INFO.: GB 2002-29526 A 20021219
WO 2003-GB5448 W 20031215

OTHER SOURCE(S): MARPAT 141:89124
GI



I



II



III

AB The invention relates to a prepn. of oxazolidinone derivs. of formula R1-A-C-B-CH2-R2 [wherein: A and B are independently selected from oxazolidinone or isoxazole derivs.; C is a biaryl group C1-C2 where C1 is benzene-1,4-diyl, thiene-2,5-diyl, or pyridine-2,5-diyl, etc., and C2 is pyridazine-3,6-diyl, pyrazine-2,5-diyl, pyrimidine-2,5-diyl, or

1,3,4-thiadiazole-2,5-diyl, etc.; R1 is CN, C(O), (un)substituted Ph or naphthyl, cycloalkyl, or heteroaryl, etc.; R2 is OH, OSi(trialkyl), or NHC(O)Me, etc.], useful as antibacterial agents. For instance, oxazolidinone deriv. I was prepd. from the obtained bromopyrimidine deriv. II and obtained trimethylstannylphenyloxazole deriv. III in the presence of palladium catalyst. For instance, antibacterial properties of I against several types of bacteria were detd. [MIC(.mu.g/mL): staphylococcus aureus (2), streptococcus pneumoniae (0.25), haemophilus influenza (8)].

IT 716379-02-1P 716379-05-4P 716379-09-8P
716379-12-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of oxazolidinone derivs., useful as antibacterial agents)

RN 716379-02-1 CAPLUS
CN 2-Oxazolidinone, 3-[4-[2-[4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl]-5-pyrimidinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 716379-05-4 CAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[2-[5-(hydroxymethyl)-2-oxo-3-oxazolidinyl]-5-thiazolyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 716379-09-8 CAPLUS
CN 2-Oxazolidinone, 3-[4-[6-[4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl]-3-pyridazinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)- (9CI) (CA INDEX NAME)



RN 716379-12-3 CAPLUS
CN 2-Oxazolidinone, 3-[4-[2-[4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl]-5-pyrimidinyl]-3-fluorophenyl]-5-[[4-(fluoromethyl)-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:292029 CAPLUS
DOCUMENT NUMBER: 140:321158
TITLE: Methods of preparation of bifunctional heterocyclic compounds for use as antiinfective, antiproliferative, antiinflammatory and prokinetic agents
INVENTOR(S): Wang, Deping; Sutcliffe, Joyce A.; Oyelere, Adegboyega K.; Mcconnell, Timothy S.; Ippolito, Joseph A.; Abelson, John N.
PATENT ASSIGNEE(S): Rib-X Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 363 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004029066	A2	20040408	WO 2003-US30478	20030926
WO 2004029066	C1	20040513		
WO 2004029066	A3	20040826		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,

TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2003278995	A1	20040419	AU 2003-278995		20030925
US 2005197334	A1	20050908	US 2003-671326		20030925
CA 2500158	AA	20040408	CA 2003-2500158		20030926
EP 1543017	A2	20050622	EP 2003-770506		20030926
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
JP 2006503848	T2	20060202	JP 2004-540011		20030926
PRIORITY APPLN. INFO.:			US 2002-414207P	P	20020926
			US 2003-448216P	P	20030219
			WO 2003-US30478	W	20030926

OTHER SOURCE(S): MARPAT 140:321158
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention provides a family of bifunctional heterocyclic compds., e.g., I [A = C, C(:O), N (with proviso, that at least one A = C); B = O, NR2, S(O)r, C(:O), C(:S), C(:NOR3); p = 0, 1; q = 0, 1; r = 0 - 2; R2 = H, S(O)rR4, CHO, C1-8-alkyl; C2-8-alkenyl, C2-8-alkynyl, C1-8-alkoxy, C1-8-alkylthio, C1-8-acyl, (un)satd. or arom. C3-8-carbocycle, (un)satd. or arom. 5 to 10-membered heterocycle (contg. one or more N, S, O); NR2R2 = 5 to 8-membered (un)satd. carbocycle or heterocycle (contg. one or more N, S, O); R3 = H, C1-8-alkyl; C2-8-alkenyl, C2-8-alkynyl, C1-8-acyl, (un)satd. or arom. C3-8-carbocycle, (un)satd. or arom. 5 to 7-membered heterocycle (contg. one or more N, S, O); NR3R3 = 5 to (un)satd. 7-membered carbocycle or heterocycle (contg. one or more N, S, O); R4 = H, NR3R3, NR3OR3, NR3NR3R3, NHCOR3, C(:O)NR3R3, C1-8-alkyl; C2-8-alkenyl, C2-8-alkynyl, etc.; D = D1, D2, D3, D4; E = di- or penta-substituted Ph, substituted 4-vinylphenyl; G = C1-4-alkyl, C5-8-alkyl, C2-8-alkenyl, C2-8-alkynyl, C1-8-alkoxy, C1-8-alkylthio, C1-8-acyl, (un)satd. or arom. C5-10-carbocycle, (un)satd. or arom. 5 to 10-membered heterocycle (contg. one or more N, S, O); Z = C,N,O,S; dashed line = single or double bond] or a pharmaceutically acceptable salt, ester or prodrug thereof, useful as antiinfective, antiproliferative, antiinflammatory and prokinetic agents (no data). The invention also provides methods of making the bifunctional hetercyclic compds., and methods of using such compds. as antiinfective, antiproliferative, antiinflammatory and/or prokinetic agents. Thus, erythromycin deriv. II was prepd. from N-(desmethylerythromycin), via N-alkylation with HC.tplbond.CCH2CH2OTs, and cycloaddn. with azide III.

IT 677726-60-2P 677726-62-4P 677726-65-7P
677727-94-5P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of bifunctional heterocyclic compds. for use as antiinfective, antiproliferative, antiinflammatory and prokinetic agents)

RN 677726-60-2 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[1-[[(5R)-3-[3-fluoro-4-(1H-1,2,3-triazol-1-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-.beta.-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 677726-62-4 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[1-[[(5R)-3-[4-[4-[(dimethylamino)methyl]-1H-1,2,3-triazol-1-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-.beta.-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 677726-65-7 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[1-[[(5R)-3-[3-fluoro-4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-.beta.-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 677727-94-5 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[2-[1-[[(5R)-3-[3-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-.beta.-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L7 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:696895 CAPLUS
DOCUMENT NUMBER: 139:214459
TITLE: Preparation of 5-azolylmethyl oxazolidinones and their use as antibacterial agents
INVENTOR(S): Gravestock, Michael Barry; Hales, Neil James; Reck, Folkert; Zhou, Fei; Fleming, Paul Robert; Carcanague, Daniel Robert
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 126 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003072576	A2	20030904	WO 2003-GB791	20030225
WO 2003072576	A3	20031231		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,

LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2477379	AA	20030904	CA 2003-2477379		20030225
AU 2003209994	A1	20030909	AU 2003-209994		20030225
EP 1480975	A2	20041201	EP 2003-742987		20030225
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
BR 2003008018	A	20050104	BR 2003-8018		20030225
CN 1653064	A	20050810	CN 2003-809160		20030225
US 2005182112	A1	20050818	US 2003-505902		20030225
JP 2005531504	T2	20051020	JP 2003-571282		20030225
ZA 2004006684	A	20050921	ZA 2004-6684		20040823
NO 2004003951	A	20041111	NO 2004-3951		20040921
PRIORITY APPLN. INFO.:			US 2002-360688P	P	20020228
			WO 2003-GB791	W	20030225

OTHER SOURCE(S): MARPAT 139:214459
GI



I



II

AB 3-Cyclyl-5-[(nitrogen-contg. 5-membered ring)methyl]oxazolidinones (shown as I; e.g. (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-azidomethyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one (shown as II); -N-HET is, for example, 3-R1-1,2,4-triazol-1-yl or 5-R1-2H-tetrazol-2-yl wherein R1 is, for example, halo or (1-4C)alkyl that is substituted by 1 substituent =, for example, OH, (1-4C)alkoxy, amino, cyano, azido; Q = for example, 3-R2-4-T-5-R3phenyl wherein R2 and R3 = H or fluoro; T = for example, 5,6-dihydro-2H-thiopyran-4-yl with 0-2 O atoms bonded to S) are useful as antibacterial agents; and processes for their manuf. and pharmaceutical compns. contg. them are described. Compds. I have a good spectrum of activity in vitro against std. organisms, which are used to screen for activity against pathogenic bacteria. For example, the min. inhibitory concns. of II against methicillin sensitive and quinolone sensitive Staphylococcus aureus and against methicillin resistant and quinolone resistant Staphylococcus aureus are 4 and 8 .mu.g/mL, resp. Compds. I showed a favorable decreased MAO-A potency compared with analogs from the known art with C-5 side chains such as acetamidomethyl or unsubstituted azolylmethyl or hydroxymethyl. They also showed favorable decreased MAO-A potency compared with analogs in which

the HET group is unsubstituted. Sixty-one example prepns. of I are included. For example, to prep. II, (5R)-3-[4-(1-oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-hydroxymethyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one (2.7 mmol) (prepn. given) was suspended in CH2Cl2 (10 mL), 1,8-diazabicyclo[5.4.0]undec-7-ene (4.7 mmol) was added and the reaction mixt. was cooled to -5.degree.; diphenylphosphoryl azide (3.25 mmol) was added dropwise and it was stirred for 18 h at room temp.; workup gave 1.02 g of II.

IT 591253-98-4P, (5R)-3-[3-Fluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl]-5-[[4-(hydroxymethyl)-1H-1,2,3-triazol-1-yl]methyl]-1,3-oxazolidin-2-one
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; prepn. of 5-azolylmethyl oxazolidinones and their use as antibacterial agents)

RN 591253-98-4 CAPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl]-5-[[4-(hydroxymethyl)-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 591253-97-3P, (5R)-3-[3-Fluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl]-5-[[4-(fluoromethyl)-1H-1,2,3-triazol-1-yl]methyl]oxazolidin-2-one
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of 5-azolylmethyl oxazolidinones and their use as antibacterial agents)

RN 591253-97-3 CAPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl]-5-[[4-(fluoromethyl)-1H-1,2,3-triazol-1-yl]methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:696894 CAPLUS
DOCUMENT NUMBER: 139:214458
TITLE: Preparation of 3-cyclyl-5-[(nitrogen-containing 5-membered ring)methyl]oxazolidinones and their use as antibacterial agents
INVENTOR(S): Gravestock, Michael Barry; Hales, Neil James; Reck, Folkert; Zhou, Fei; Fleming, Paul Robert; Carcanague, Daniel Robert; Girardot, Marc Michel
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 140 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2003072575	A1	20030904	WO 2003-GB785		20030225
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2477344	AA	20030904	CA 2003-2477344		20030225
AU 2003207340	A1	20030909	AU 2003-207340		20030225
BR 2003008056	A	20041207	BR 2003-8056		20030225
EP 1497286	A1	20050119	EP 2003-704812		20030225
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
US 2005119292	A1	20050602	US 2003-506020		20030225
CN 1649866	A	20050803	CN 2003-809171		20030225
JP 2005524661	T2	20050818	JP 2003-571281		20030225
ZA 2004006812	A	20050912	ZA 2004-6812		20040826
NO 2004003950	A	20041013	NO 2004-3950		20040921
PRIORITY APPLN. INFO.:			US 2002-360957P	P	20020228
			WO 2003-GB785	W	20030225

OTHER SOURCE(S): MARPAT 139:214458
GI



I



II

AB 3-Cyclyl-5-[(nitrogen-contg. 5-membered ring)methyl]oxazolidinones (shown as I; e.g. (5R)-3-[4-(1-oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[4-methyl-1,2,3-triazol-1-ylmethyl]oxazolidin-2-one (shown as II); -N-HET is, for example, 3-R1-1,2,4-triazol-1-yl or 5-R1-2H-tetrazol-2-yl wherein R1 is (1-4C)alkyl; Q = for example, 3-R2-4-T-5-R3phenyl wherein R2 and R3 = H or fluoro; T = for example, 5,6-dihydro-2H-thiopyran-4-yl with 0-2 O atoms bonded to S), or a pharmaceutically-acceptable salt, or an in-vivo-hydrolyzable ester thereof, are useful as antibacterial agents; and processes for their manuf. and pharmaceutical compns. contg. them are described. Compds. I have a good spectrum of activity in vitro against std. organisms, which are used to screen for activity against pathogenic bacteria. For example, the min. inhibitory concns. of II against methicillin sensitive and quinolone sensitive Staphylococcus aureus and against methicillin resistant and quinolone resistant Staphylococcus aureus are 2 and 4 .mu.g/mL, resp., compared to 2 and 2 .mu.g/mL for the ref. compd. without the Me substituent. Compds. I showed a favorable decreased MAO-A potency compared with analogs from the known art with C-5 side chains such as acetamidomethyl or unsubstituted azolylmethyl or hydroxymethyl. They also showed favorable decreased MAO-A potency compared with analogs in which the HET group is unsubstituted. Fifty-seven example prepns. of intermediates and 44 example prepns. of I are included. For example, to prep. II, (5R)-3-[4-(1-oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-azidomethyloxazolidin-2-one (1.0 mmol; prepn. described) was mixed with 5,6,7,8-tetrachloro-2,9-dimethyl-1,4-dihydro-1,4-ethenonaphthalene (2.0 mmol) in dry 1,4-dioxane (4 mL) in a sealed microwave reaction tube. The tube was placed in a Smith microwave reactor at 170.degree. for 20 min. The reaction mixt. was then transferred into a round bottom flask and the solvent was removed under vacuum. The residue was purified by chromatog. on silica gel with 5% MeOH in CH2Cl2 to give a mixt. of the 4- and 5-Me regioisomers. This mixt. was further sepd. on a chiral column (chiralcel OD) with iso-PrOH/hexanes (1:1) to give II (74 mg).

IT 591232-13-2P, (5R)-3-[3-Fluoro-4-(4-bromo-1H-imidazol-1-yl)phenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one
591232-15-4P, (5R)-3-[3-Fluoro-4-(4-methyl-1,2,3-triazol-1-yl)phenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one
591232-23-4P, (5R)-3-[3-Fluoro-4-(3-methyl-1,2,4-triazol-1-yl)phenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one
591232-31-4P, (5R)-3-[3-Fluoro-4-[4-[(hydroxyimino)methyl]imidazol-1-yl]phenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one

591232-42-7P, (5R)-3-[3-Fluoro-4-[4-formylimidazol-1-yl]phenyl]-5-[(4-pentyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591232-43-8P, (5R)-3-[3-Fluoro-4-[4-(hydroxymethyl)-1H-imidazol-1-yl]phenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591232-46-1P, (5R)-3-[3-Fluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591232-49-4P, (5R)-3-[3-Fluoro-4-(1H-imidazol-1-yl)phenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591232-50-7P, (5R)-3-[3-Fluoro-4-(4-cyano-1H-pyrazol-1-yl)phenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of cyclyl (nitrogen-contg. 5-membered ring)methyl oxazolidinones and their use as antibacterial agents)

RN 591232-13-2 CAPLUS
CN 2-Oxazolidinone, 3-[4-(4-bromo-1H-imidazol-1-yl)-3-fluorophenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591232-15-4 CAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(4-methyl-1H-1,2,3-triazol-1-yl)phenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591232-23-4 CAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591232-31-4 CAPLUS
CN 1H-Imidazole-4-carboxaldehyde, 1-[2-fluoro-4-[(5R)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl]phenyl]-, 4-oxime (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 591232-42-7 CAPLUS
CN 1H-Imidazole-4-carboxaldehyde, 1-[2-fluoro-4-[(5R)-2-oxo-5-[(4-pentyl-1H-1,2,3-triazol-1-yl)methyl]-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591232-43-8 CAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[4-(hydroxymethyl)-1H-imidazol-1-yl]phenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591232-46-1 CAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591232-49-4 CAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(1H-imidazol-1-yl)phenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591232-50-7 CAPLUS
CN 1H-Pyrazole-4-carbonitrile, 1-[2-fluoro-4-[(5R)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 591232-44-9P, (5R)-3-[4-[4-[(tert-Butyldimethylsilyloxy)methyl]-1H-imidazol-1-yl]-3-fluorophenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of cyclyl (nitrogen-contg. 5-membered ring)methyl oxazolidinones and their use as antibacterial agents)
RN 591232-44-9 CAPLUS
CN 2-Oxazolidinone, 3-[4-[4-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-1H-imidazol-1-yl]-3-fluorophenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:335104 CAPLUS
DOCUMENT NUMBER: 138:353972
TITLE: Preparation of 3-aryloxazolidinones with antibacterial activity
INVENTOR(S): Gravestock, Michael Barry
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 80 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003035648	A1	20030501	WO 2002-GB4796	20021023

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,

LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

GB 2396350	A1	20040623	GB 2004-8399		20021023
EP 1446403	A1	20040818	EP 2002-770098		20021023
EP 1446403	B1	20060412			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK					
JP 2005519870	T2	20050707	JP 2003-538164		20021023
AT 323087	E	20060415	AT 2002-770098		20021023
US 2005043374	A1	20050224	US 2004-493609		20041018
PRIORITY APPLN. INFO.:			US 2001-330589P	P	20011025
			WO 2002-GB4796	W	20021023

OTHER SOURCE(S): MARPAT 138:353972
GI



I





II

AB Title compds. I [wherein HET = (un)substituted N-linked 5-membered heterocyclic or 6-membered dihydroheteroaryl ring contg. heteroatoms selected from N, O, and S; Q = Q1, Q2, etc.; R2 and R3 = independently H or F; T = (un)substituted C-linked 5-membered heteroaryl contg. 1-3 heteroatoms selected from N, O, and S; preferably T = (un)substituted 1,3,4-thiadiazolyl, thiazolyl, 1,3,4-oxadiazolyl, or oxazolyl; and pharmaceutically acceptable salts or hydrolyzable esters thereof] were prepd. as antibacterial agents. For example, (5R)-3-(3-fluoro-4-iodophenyl)-5-hydroxymethyl-1,3-oxazolidin-2-one was mesylated and the product converted to the azide. Cyclization of the azide with bicyclo[2.2.1]heptadiene gave the 1,2,3-triazole, which was substituted with hexamethylditin to afford the stannane. Reaction with 5-chloro-1,3,4-thiadiazole-2-carbonitrile in the presence of AsPh3 and tris(dibenzylidenenacetone)dipalladium in N-methyl-2-pyrrolidinone provided II. The latter inhibited bacterial growth against Staphylococcus aureus (methicillin sensitive and quinolone sensitive), Staphylococcus aureus (methicillin resistant and quinolone resistant), Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae, and Moraxella

catarrhalis with MIC values of 0.125 .mu.g/mL, 0.25 .mu.g/mL, 0.125 .mu.g/mL, 0.125 .mu.g/mL, 2 .mu.g/mL, and 0.5 .mu.g/mL,resp.

IT 519003-00-0P, (5R)-3-[3-Fluoro-4-(5-cyano-1,3,4-thiadiazol-2-yl)phenyl]-5-[(1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 519003-02-2P, (5R)-3-[3-Fluoro-4-(5-ethoxycarbonyl-1,3,4-thiadiazol-2-yl)phenyl]-5-[(1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 519003-03-3P, (5R)-3-[4-[5-(Aminomethyl)-1,3-thiazol-2-yl]-3-fluorophenyl]-5-[(1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 519003-05-5P, (5R)-3-[3-Fluoro-4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]-5-[(1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 519003-11-3P, (5R)-3-[3-Fluoro-4-(4-methyl-1,3-thiazol-2-yl)phenyl]-5-[(1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 519003-14-6P, (5R)-3-[3-Fluoro-4-[4-(trifluoromethyl)-1,3-thiazol-2-yl]phenyl]-5-[(1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 519003-16-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(antibacterial agent; prepn. of (aryl)oxazolidinones as antibacterial agents)

RN 519003-00-0 CAPLUS

CN 1,3,4-Thiadiazole-2-carbonitrile, 5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 519003-02-2 CAPLUS

CN 1,3,4-Thiadiazole-2-carboxylic acid, 5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 519003-03-3 CAPLUS

CN 2-Oxazolidinone, 3-[4-[5-(aminomethyl)-2-thiazolyl]-3-fluorophenyl]-5-(1H-

1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 519003-05-5 CAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 519003-11-3 CAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(4-methyl-2-thiazolyl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 519003-14-6 CAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[4-(trifluoromethyl)-2-thiazolyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 519003-16-8 CAPLUS
CN 1,3,4-Thiadiazole-2-acetonitrile, 5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 519003-15-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of (aryl)oxazolidinones as antibacterial agents)
RN 519003-15-7 CAPLUS
CN 2-Oxazolidinone, 3-[4-[4,5-dihydro-4-hydroxy-4-(trifluoromethyl)-2-thiazolyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:798227 CAPLUS
DOCUMENT NUMBER: 135:344473
TITLE: Oxazolidinone derivatives with antibacterial activity
INVENTOR(S): Gravestock, Michael Barry; Betts, Michael John;

	Griffin, David Alan; Matthews, Ian Richard
PATENT ASSIGNEE(S):	Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE:	PCT Int. Appl., 143 pp.
	CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001081350	A1	20011101	WO 2001-GB1815	20010423
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2405349	AA	20011101	CA 2001-2405349	20010423
BR 2001010240	A	20030107	BR 2001-10240	20010423
EP 1286998	A1	20030305	EP 2001-921669	20010423
EP 1286998	B1	20040609		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003531211	T2	20031021	JP 2001-578439	20010423
EE 200200598	A	20040415	EE 2002-598	20010423
NZ 521765	A	20040528	NZ 2001-521765	20010423
AT 268778	E	20040615	AT 2001-921669	20010423
PT 1286998	T	20040930	PT 2001-921669	20010423
ES 2220759	T3	20041216	ES 2001-1921669	20010423
AU 781784	B2	20050616	AU 2001-48636	20010423
ZA 2002008187	A	20040211	ZA 2002-8187	20021010
NO 2002005091	A	20021209	NO 2002-5091	20021023
US 2003216373	A1	20031120	US 2003-258355	20030506
HK 1053114	A1	20050218	HK 2003-105394	20030725
PRIORITY APPLN. INFO.:			GB 2000-9803 A	20000425
			WO 2001-GB1815 W	20010423

OTHER SOURCE(S):	MARPAT 135:344473
GI	



I



II



III



IV



V

AB The title compds. [I; X = O, NH, S, etc.; HET = (un)substituted C-linked 5-membered heteroaryl ring contg. 2-4 heteroatoms selected from N, O and S, etc.; Q = II, III, etc. (wherein R2, R3 = H, F; T = an N-linked (fully unsatd.) 5-membered heteroaryl ring system or IV; Rc = R13CO, R13SO2, R13CS, etc.; R13 = alkyl, etc.)], useful as antibacterial agents, were prepd. and formulated. E.g., a multi-step synthesis of the oxazoline (R)-V which showed MIC of 0.125 .mu.g/mL against Staphylococcus aureus (Oxford), was given.

IT 371194-46-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(oxazolidinone derivs. with antibacterial activity)

RN 371194-46-6 CAPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-(1H-imidazol-1-yl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT